These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

104 related articles for article (PubMed ID: 3096087)

  • 1. [Deprenyl as a co-adjuvant in the treatment of Parkinson disease].
    Ferrari E; Cacudi N; de Mari M; Iliceto G; Lamberti P
    Acta Neurol (Napoli); 1986 Aug; 8(4):455-61. PubMed ID: 3096087
    [No Abstract]   [Full Text] [Related]  

  • 2. Deprenyl in the treatment of Parkinson's disease. A specific type B monoamine oxidase inhibitor.
    Lieberman AN; Gopinathan G; Neophytides A; Hiesiger E; Nelson J; Walker R; Goodgold A
    N Y State J Med; 1984 Jan; 84(1):13-6. PubMed ID: 6422358
    [No Abstract]   [Full Text] [Related]  

  • 3. Deprenyl prolongs the therapeutic efficacy of combined L-DOPA in Parkinson's disease.
    Birkmayer W; Riederer P
    Adv Neurol; 1984; 40():475-81. PubMed ID: 6421111
    [No Abstract]   [Full Text] [Related]  

  • 4. [Slowing the progression of Parkinson syndrome by early administration of deprenyl].
    Baas H; Fischer PA
    Nervenarzt; 1990 Feb; 61(2):127-9. PubMed ID: 2108395
    [No Abstract]   [Full Text] [Related]  

  • 5. [Biochemical basis for using selective monoamine oxidase inhibitors in the treatment of Parkinson's disease. Critical contribution].
    Amato L; Nava L; Rizzo M; Piccoli F
    Riv Neurol; 1985; 55(1):46-52. PubMed ID: 3927468
    [No Abstract]   [Full Text] [Related]  

  • 6. MPTP: clinical implications.
    Stern G
    J Neural Transm Suppl; 1986; 20():77-81. PubMed ID: 3091763
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Clinicopharmacological study of long-term Jumex + Dopaflex combination treatment in Parkinson's syndrome.
    Antóny M; Tóth G; Széplaki Z
    Ther Hung; 1982; 30(4):168-71. PubMed ID: 6821398
    [No Abstract]   [Full Text] [Related]  

  • 8. Early combination with deprenyl: a retrospective analysis.
    Fornadi F; Ulm G
    Adv Neurol; 1990; 53():437-40. PubMed ID: 2122650
    [No Abstract]   [Full Text] [Related]  

  • 9. Clinical evaluation of selegiline (L-deprenyl) in the long-term L-dopa treatment syndrome.
    Trebini F; Daniele D; Gillio S; Scarzella L
    Acta Neurol (Napoli); 1985 Oct; 7(5):432-9. PubMed ID: 3933283
    [No Abstract]   [Full Text] [Related]  

  • 10. Dose regimen of deprenyl (selegiline) and platelet MAO activities.
    Oreland L; Johansson F; Ekstedt J
    Acta Neurol Scand Suppl; 1983; 95():87-9. PubMed ID: 6428150
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Combination therapy of parkinsonism with deprenyl.
    Behari M; Ahuja GK; Singh K; Prasad K
    J Assoc Physicians India; 1992 Jun; 40(6):365-7. PubMed ID: 1452557
    [TBL] [Abstract][Full Text] [Related]  

  • 12. R-(-)-deprenyl as an adjuvant to levodopa in the treatment of Parkinson's disease.
    Rinne UK
    J Neural Transm Suppl; 1987; 25():149-55. PubMed ID: 3123601
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The effect of R-(-)-deprenyl in de novo Parkinson patients on combination therapy with levodopa and decarboxylase inhibitor.
    Przuntek H; Kuhn W
    J Neural Transm Suppl; 1987; 25():97-104. PubMed ID: 3123607
    [TBL] [Abstract][Full Text] [Related]  

  • 14. R-(-)-deprenyl as a possible protective agent in Parkinson's disease.
    Tetrud JW; Langston JW
    J Neural Transm Suppl; 1987; 25():69-79. PubMed ID: 3123606
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Deprenyl in Parkinson's disease.
    Lancet; 1982 Sep; 2(8300):695-6. PubMed ID: 6126632
    [No Abstract]   [Full Text] [Related]  

  • 16. Two weeks of treatment with deprenyl (selegiline) does not prolong L-dopa effect in parkinsonian patients: a double-blind cross-over placebo-controlled trial.
    Rascol O; Montastruc JL; Senard JM; Demonet JF; Simonetta M; Rascol A
    Neurology; 1988 Sep; 38(9):1387-91. PubMed ID: 3137488
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Protective effect of selegiline in the early and late phases of Parkinson's disease.
    Csanda E; Tárczy M
    Adv Neurol; 1993; 60():672-5. PubMed ID: 8420208
    [No Abstract]   [Full Text] [Related]  

  • 18. The effects of early selegiline therapy on long-term levodopa treatment and parkinsonian disability: an interim analysis of a Norwegian--Danish 5-year study. Norwegian-Danish Study Group.
    Larsen JP; Boas J
    Mov Disord; 1997 Mar; 12(2):175-82. PubMed ID: 9087975
    [TBL] [Abstract][Full Text] [Related]  

  • 19. L-deprenyl in the treatment of Parkinson's disease.
    Csanda E; Tárczy M; Takáts A; Mogyorós I; Köves A; Katona G
    J Neural Transm Suppl; 1983; 19():283-90. PubMed ID: 6421993
    [TBL] [Abstract][Full Text] [Related]  

  • 20. R-(-)-deprenyl and parkinsonism.
    Yahr MD
    J Neural Transm Suppl; 1987; 25():5-12. PubMed ID: 3123605
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.